Reduction of in-stent thrombus immediately after percutaneous coronary intervention by pretreatment with prasugrel compared with clopidogrel: An optical coherence tomography study

Journal of Cardiology

Volumn 69, Issue 2, 2017, Pages 436-441

  Kubo, Takashi ^a   Ino, Yasushi ^a   Matsuo, Yoshiki ^a   Shiono, Yasutsugu ^a   Kameyama, Takeyoshi ^a   Yamano, Takashi ^a   Katayama, Yosuke ^a   Taruya, Akira ^a   Nishiguchi, Tsuyoshi ^a   Satogami, Keisuke ^a   Kashiyama, Kuninobu ^a   Orii, Makoto ^a   Kuroi, Akio ^a   Yamaguchi, Tomoyuki ^a   Tanaka, Atsushi ^a   Hozumi, Takeshi ^a   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute coronary syndrome; Optical coherence tomography; Prasugrel; Stent; Thrombus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; CREATINE KINASE MB; PRASUGREL; TICLOPIDINE; WARFARIN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; BALLOON DILATATION; BARE METAL STENT; CARDIOVASCULAR RISK; DRUG ELUTING CORONARY STENT; EVEROLIMUS ELUTING CORONARY STENT; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; DIAGNOSTIC IMAGING; FEMALE; MALE; PLAQUE, ATHEROSCLEROTIC; PREMEDICATION; STENT; THROMBOSIS;

ACUTE CORONARY SYNDROME; AGED; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PREMEDICATION; RETROSPECTIVE STUDIES; STENTS; THROMBOSIS; TICLOPIDINE; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84975487608     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2016.04.005     Document Type: Article

References (27)

1. [1] Mehta, S.R., Yusuf, S., Peters, R.J., Bertrand, M.E., Lewis, B.S., Natarajan, M.K., Malmberg, K., Rupprecht, H., Zhao, F., Chrolavicius, S., Copland, I., Fox, K.A., for the Clopidogrel in Unstable Angina to Prevent Recurrent Events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001), 527–533.
2. [2] Brandt, J.T., Close, S.L., Iturria, S.J., Payne, C.D., Farid, N.A., Ernest, C.S. 2nd, Lachno, D.R., Salazar, D., Winters, K.J., Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5 (2007), 2429–2436.
3. [3] Cattaneo, M., New P2Y12 inhibitors. Circulation 121 (2010), 171–179.
4. [4] Nakamura, M., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Ikeda, Y., Saito, S., Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study. Int J Cardiol 182 (2015), 541–548.
5. [5] Kubo, T., Akasaka, T., Shite, J., Suzuki, T., Uemura, S., Yu, B., Kozuma, K., Kitabata, H., Shinke, T., Habara, M., Saito, Y., Hou, J., Suzuki, N., Zhang, S., OCT compared with IVUS in a coronary lesion assessment: the OPUS-CLASS study. JACC Cardiovasc Imaging 6 (2013), 1095–1104.
6. [6] Braunwald, E., Antman, E.M., Beasley, J.W., Califf, R.M., Cheitlin, M.D., Hochman, J.S., Jones, R.H., Kereiakes, D., Kupersmith, J., Levin, T.N., Pepine, C.J., Schaeffer, J.W., Smith, E.E. 3rd, Steward, D.E., Theroux, P., et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106 (2002), 1893–1900.
7. [7] Chesebro, J.H., Knatterud, G., Roberts, R., Borer, J., Cohen, L.S., Dalen, J., Dodge, H.T., Francis, C.K., Hillis, D., Ludbrook, P., Markis, J.E., Mueller, H., Passamani, E.R., Powers, E.R., Rao, A.K., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987), 142–154.
8. [8] Svilaas, T., Vlaar, P.J., van der Horst, I.C., Diercks, G.F., de Smet, B.J., van den Heuvel, A.F., Anthonio, R.L., Jessurun, G.A., Tan, E.S., Suurmeijer, A.J., Zijlstra, F., Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358 (2008), 557–567.
9. [9] Tearney, G.J., Regar, E., Akasaka, T., Adriaenssens, T., Barlis, P., Bezerra, H.G., Bouma, B., Bruining, N., Cho, J.M., Chowdhary, S., Costa, M.A., de Silva, R., Dijkstra, J., Di Mario, C., Dudek, D., et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 59 (2012), 1058–1072.
10. [10] Jia, H., Abtahian, F., Aguirre, A.D., Lee, S., Chia, S., Lowe, H., Kato, K., Yonetsu, T., Vergallo, R., Hu, S., Tian, J., Lee, H., Park, S.J., Jang, Y.S., Raffel, O.C., et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol 62 (2013), 1748–1758.
11. [11] Higuma, T., Soeda, T., Abe, N., Yamada, M., Yokoyama, H., Shibutani, S., Vergallo, R., Minami, Y., Ong, D.S., Lee, H., Okumura, K., Jang, I.K., A combined optical coherence tomography and intravascular ultrasound study on plaque rupture, plaque erosion, and calcified nodule in patients with ST-segment elevation myocardial infarction: incidence, morphologic characteristics, and outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv 8 (2015), 1166–1176.
12. [12] Kubo, T., Akasaka, T., Kozuma, K., Kimura, K., Fusazaki, T., Okura, H., Shinke, T., Ino, Y., Hasegawa, T., Takashima, H., Takamisawa, I., Yamaguchi, H., Igarashi, K., Kadota, K., Tanabe, K., et al. Vascular response to drug-eluting stent with biodegradable vs. durable polymer. Optical coherence tomography substudy of the NEXT. Circ J 78 (2014), 2408–2414.
13. [13] Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Nishikawa, M., Miyazaki, S., Ikeda, Y., Nakamura, M., Saito, S., PRASFIT-Elective Investigators. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circ J 78 (2014), 2926–2934.
14. [14] Mauri, L., Hsieh, W.H., Massaro, J.M., Ho, K.K., D'Agostino, R., Cutlip, D.E., Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007), 1020–1029.
15. [15] Mehran, R., Rao, S.V., Bhatt, D.L., Gibson, C.M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S.D., Menon, V., Nikolsky, E., Serebruany, V., Valgimigli, M., Vranckx, P., Taggart, D., Sabik, J.F., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
16. [16] Stone, G.W., Witzenbichler, B., Weisz, G., Rinaldi, M.J., Neumann, F.J., Metzger, D.C., Henry, T.D., Cox, D.A., Duffy, P.L., Mazzaferri, E., Gurbel, P.A., Xu, K., Parise, H., Kirtane, A.J., Brodie, B.R., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (2013), 614–623.
17. [17] Nakano, M., Yahagi, K., Otsuka, F., Sakakura, K., Finn, A.V., Kutys, R., Ladich, E., Fowler, D.R., Joner, M., Virmani, R., Causes of early stent thrombosis in patients presenting with acute coronary syndrome: an ex vivo human autopsy study. J Am Coll Cardiol 63 (2014), 2510–2520.
18. [18] Choi, S.Y., Witzenbichler, B., Maehara, A., Lansky, A.J., Guagliumi, G., Brodie, B., Kellett, M.A. Jr., Dressler, O., Parise, H., Mehran, R., Dangas, G.D., Mintz, G.S., Stone, G.W., Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. Circ Cardiovasc Interv 4 (2011), 239–247.
19. [19] Hong, Y.J., Jeong, M.H., Choi, Y.H., Park, S.Y., Rhew, S.H., Jeong, H.C., Cho, J.Y., Jang, S.Y., Lee, K.H., Park, K.H., Sim, D.S., Yoon, N.S., Yoon, H.J., Kim, K.H., Park, H.W., et al. Clinical, angiographic, and intravascular ultrasound predictors of early stent thrombosis in patients with acute myocardial infarction. Int J Cardiol 168 (2013), 1674–1675.
20. [20] Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.J., Ardissino, D., De Servi, S., Murphy, S.A., Riesmeyer, J., Weerakkody, G., Gibson, C.M., Antman, E.M., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
21. [21] Brener, S.J., Oldroyd, K.G., Maehara, A., El-Omar, M., Witzenbichler, B., Xu, K., Mehran, R., Gibson, C.M., Stone, G.W., Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Am J Cardiol 113 (2014), 1457–1460.
22. [22] Erlinge, D., Ten Berg, J., Foley, D., Angiolillo, D.J., Wagner, H., Brown, P.B., Zhou, C., Luo, J., Jakubowski, J.A., Moser, B., Small, D.S., Bergmeijer, T., James, S., Winters, K.J., Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 60 (2012), 2032–2040.
23. [23] Erlinge, D., Gurbel, P.A., James, S., Lindahl, T.L., Svensson, P., Ten Berg, J.M., Foley, D.P., Wagner, H., Brown, P.B., Luo, J., Zhou, C., Moser, B.A., Jakubowski, J.A., Small, D.S., Winters, K.J., et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 62 (2013), 577–583.
24. [24] Saito, S., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Nishikawa, M., Miyazaki, S., Nakamura, M., Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 78 (2014), 1684–1692.
25. [25] Jang, J.S., Cho, K.I., Jin, H.Y., Seo, J.S., Yang, T.H., Kim, D.K., Kim, D.S., Seol, S.H., Kim, D.I., Kim, B.H., Park, Y.H., Je, H.G., Jeong, Y.H., Lee, S.W., Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 110 (2012), 502–508.
26. [26] Kawai, H., Watanabe, E., Yamamoto, M., Harigaya, H., Sano, K., Takatsu, H., Muramatsu, T., Naruse, H., Sobue, Y., Motoyama, S., Sarai, M., Takahashi, H., Arakawa, T., Kan, S., Sugiura, A., et al. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. J Cardiol 65 (2015), 197–202.
27. [27] Kubo, T., Shinke, T., Okamura, T., Hibi, K., Nakazawa, G., Morino, Y., Shite, J., Fusazaki, T., Otake, H., Kozuma, K., Akasaka, T., Optical frequency domain imaging vs. intravascular ultrasound in percutaneous coronary intervention (OPINION trial): study protocol for a randomized controlled trial. J Cardiol, 2016, 10.1016/j.jjcc.2015.11.007.